Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder - Full Text View

Sponsor:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00036101

Purpose

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.

Condition	Intervention	Phase
Bipolar Disorder	Drug: aripiprazole	Phase III

Study Type:	Interventional
Study Design:	Treatment

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder

Drug Information available for: Aripiprazole

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036101

Hide Study Locations

Locations

United States, Alabama
Local Institution
Tuscaloosa, Alabama, United States
United States, Arizona
Local Institution
Little Rock, Arizona, United States
United States, California
Local Institution
Chula Vista, California, United States
Local Institution
Stanford, California, United States
Local Institution
San Clemente, California, United States
Local Institution
Beachwood, California, United States
Local Institution
San Diego, California, United States
Local Institution
Riverside, California, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Winter Park, Florida, United States
Local Institution
North Miami, Florida, United States
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Indiana
Local Institution
Indianapolis, Indiana, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Massachusetts
Local Institution
Belmont, Massachusetts, United States
Local Institution
Newton Center, Massachusetts, United States
United States, Michigan
Local Institution
New Baltimore, Michigan, United States
United States, New York
Local Institution
Lawrence, New York, United States
United States, North Carolina
Local Institution
Butner, North Carolina, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
Local Institution
Medina, Ohio, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Houston, Texas, United States
United States, Virginia
Local Institution
Falls Church, Virginia, United States
United States, Washington
Local Institution
Bellevue, Washington, United States

Sponsors and Collaborators

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CN138-074
Study First Received:	May 7, 2002
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00036101 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Bipolar I Disorder

Additional relevant MeSH terms:

Disease
Tranquilizing Agents
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Antipsychotic Agents
Pharmacologic Actions

Affective Disorders, Psychotic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Mood Disorders
Aripiprazole
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 27, 2009